A Confirmatory Study of JNS013 in Patients With Post-tooth-extraction Pain

This study has been completed.
Sponsor:
Information provided by:
Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier:
NCT00737048
First received: August 14, 2008
Last updated: February 9, 2012
Last verified: February 2012
  Purpose

The purpose of this study is to evaluate the effectiveness and safety of JNS013 with single oral dose administration in patients with post-tooth-extraction pain with extraction of mandibular impacted wisdom tooth. In addition, the significance of JNS013 as a combination drug and its usefulness in post-tooth-extraction pain will be verified, compared with single oral dose administration of tramadol hydrochloride (TRAM) or acetaminophen (APAP).


Condition Intervention Phase
Pain
Postoperative
Drug: Tramadol Hydrochloride /Acetaminophen and Placebo
Drug: Tramadol Hydrochloride and Placebo
Drug: Acetaminophen and Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-blind Comparative Study of JNS013 in Patients With Post-tooth-extraction Pain

Resource links provided by NLM:


Further study details as provided by Janssen Pharmaceutical K.K.:

Primary Outcome Measures:
  • Effectiveness of JNS013 to TRAM and APAP ; Total pain relief over 8 hours (TOTPAR 0-8 hr); as measured by the numerical rating scale of 0 (complete relief) to 4 (no relief). [ Time Frame: From the baseline (after tooth extraction but before the study drug administration) to 8 hours after the study drug administration. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Total pain relief (TOTPAR ) at each assesement period as measured by the numerical rating scale of 0 (complete relief) to 4 (no relief). [ Time Frame: From the baseline (after tooth extraction but before the study drug administration) to 4 hours after the study drug administration (0-4 hours), and 4-8 hours ] [ Designated as safety issue: No ]
  • Sum of pain intensity difference (SPID) (0-8 hr, 0-4 hr, 4-8 hr), pain relief combined with pain intensity difference (SPRID) (0-8 hr, 0-4 hr, 4-8 hr) as measured by the numerical rating scale of 0 (complete relief) to 4 (no relief). [ Time Frame: From the baseline (after tooth extraction but before the study drug administration) to 8 hours after the study drug administration ] [ Designated as safety issue: No ]
  • The mean and mean changes over time for VAS24 score as measured by VAS. [ Time Frame: From the baseline (after tooth extraction but before the study drug administration) to 8 hours after the study drug administration ] [ Designated as safety issue: No ]
  • The mean and mean changes over time for Pain intensity difference (PID), Pain relief rating (PAR), Pain Relief combined with pain Intensity Difference (PRID) as measured by the numerical rating scale of 0 (complete relief) to 4 (no relief). [ Time Frame: From the baseline (after tooth extraction but before the study drug administration) to 8 hours after the study drug administration ] [ Designated as safety issue: No ]
  • Time from investigational treatment to drug response (time to response);Time from drug response to recurrence of pain (duration of response) [ Time Frame: From the baseline (after tooth extraction but before the study drug administration) to 8 hours after the study drug administration ] [ Designated as safety issue: No ]

Enrollment: 396
Study Start Date: March 2008
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 001
Tramadol Hydrochloride /Acetaminophen and Placebo 2 tablets containing active drug and 2 tablets of placebo
Drug: Tramadol Hydrochloride /Acetaminophen and Placebo
2 tablets containing active drug and 2 tablets of placebo
Experimental: 002
Tramadol Hydrochloride and Placebo 2 tablets containing active drug and 2 tablets of placebo
Drug: Tramadol Hydrochloride and Placebo
2 tablets containing active drug and 2 tablets of placebo
Experimental: 003
Acetaminophen and Placebo 2 tablets containing active drug and 2 tablets of placebo
Drug: Acetaminophen and Placebo
2 tablets containing active drug and 2 tablets of placebo

Detailed Description:

JNS013 is a combination of tramadol hydrochloride (TRAM) acting as a weak opioid with acetaminophen (APAP). It is expected to have an intermediate effect between narcotic analgesics and NSAIDs (non-steroid anti-inflammatory drugs). Both TRAM and APAP, the active ingredients of JNS013, were approved in Japan and have been in use for years. APAP is a medication with the indication for "post-dental-treatment pain". This study is an active drug-controlled, double-blind (neither patient nor physician knows the assigned study drug medication name ), parallel-group, comparative study to exclude biases in effectiveness and safety assessments, and verify the significance of combination of JNS013 versus TRAM and APAP with the indication for "post-dental-treatment pain". Patients with post-tooth-extraction of mandibular impacted wisdom tooth will be enrolled. The 8 hour period after the study drug administration will be considered the double-blind period. Patients who meet the criteria for the double-blind period will receive the study drug as a single oral dose within 30 minitues after scoring at least 50.0 mm in VAS (Visual Analog Scale) after tooth-extraction. The JNS013 group receives 2 tabs of JNS013 and 2 capsules of placebo. TRAM group receives 2 tabs of TRAM and 2 capsules of placebo. APAP group receives 2 tabs of APAP and 2 capsules of placebo.

  Eligibility

Ages Eligible for Study:   20 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients planned to receive a tooth extraction of one mandibular impacted wisdom tooth
  • Patients who require bone removal and separation of the crown at tooth extraction

Exclusion Criteria:

  • Patients with conditions for which TRAM are contraindicated
  • Patients with conditions for which APAP are contraindicated
  • Patients with history of convulsions or the possibility of convulsive seizures
  • Pregnant patients or those who may be pregnant, lactating mothers, and those who wish pregnancy during the study period
  • Patients with concurrent, previous, or possible alcohol dependence, drug dependence or narcotic addiction
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00737048

Locations
Japan
Bunkyo, Japan
Isehara, Japan
Kitakyushu, Japan
Kumamoto N/A, Japan
Ohta-Ku, Japan
Osaka, Japan
Sapporo, Japan
Shimotsuga, Japan
Shimotsuke, Japan
Shinjuku, Japan
Yokohama N/A, Japan
Yokosuka, Japan
Sponsors and Collaborators
Janssen Pharmaceutical K.K.
Investigators
Study Director: Janssen Pharmaceutical K.K. Clinical Trial Janssen Pharmaceutical K.K.
  More Information

Additional Information:
No publications provided

Responsible Party: Director of Clinical R&D Dept. 3, Janssen Pharmaceutical K.K., Japan
ClinicalTrials.gov Identifier: NCT00737048     History of Changes
Other Study ID Numbers: CR015109, JNS013-JPN-03
Study First Received: August 14, 2008
Last Updated: February 9, 2012
Health Authority: Japan: Japan Pharmaceuticals And Medical Devices Evaluation Center

Keywords provided by Janssen Pharmaceutical K.K.:
Pain
Tooth extraction
Oral surgery
Postoperative pain
Tramadol hydrochloride
Acetaminophen

Additional relevant MeSH terms:
Acetaminophen
Tramadol
Antipyretics
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Narcotics
Central Nervous System Depressants
Analgesics, Opioid

ClinicalTrials.gov processed this record on June 17, 2013